

Wellnex Life Limited (ASX:WNX)

Wellnex obtains Market Authorisation with TGA for Liquid Paracetamol plus Caffeine Soft Gel

Highlights

- Market Authorisation (MA) received for Liquid Paracetamol plus Caffeine Soft Gel
- Builds on the Company's three other MAs
 - Liquid Paracetamol
 - Liquid Paracetamol plus Ibuprofen
 - Liquid Mini-Ibuprofen
- Validation of Company's innovation to achieve 4 MAs with the Therapeutic Goods of Australia (TGA)
- Further revenue opportunities with new MA, with existing MA's being used by the Company and domestic and global companies

Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company") is pleased to announce the approval of a new Market Authorisation (MA) for a liquid paracetamol plus caffeine soft gel after the successful submission with TGA of the pharmaceutical dossier.

The new MA approval builds on the extensive soft gel portfolio of the Company with MA's including:

- Liquid Paracetamol
- Liquid Paracetamol plus Ibuprofen
- Liquid Mini-Ibuprofen

Wellnex Life's four MAs for a range of liquid soft gels is a validation of the Company's philosophy of being either 'first' or 'fast' to market with innovative products for the consumer health market.

The approval of the new MA will further drive additional revenue opportunities for Wellnex Life, that build on the Company's existing MAs being utilised by domestic and international companies like Chemist Warehouse and Haleon.

Managing Director, Zack Bozinovski said, "The approval of liquid paracetamol plus caffeine soft gel market authorisation is a great testament to the Company and its internal capabilities. This unique product will provide opportunities not only to use in the Company's own brands but also opportunities to license it to third parties."

The ASX announcement has been authorised by the board of Wellnex Life Limited (ASX:WNX).

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au



About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/